Analytical Data
-
基因名
HLA-A*11:01&B2M&KRAS G12D(VVVGADGVGK) Tetramer
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGADGVGK
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*11:01/B2M/KRAS G12D (VVVGADGVGK) tetramer recombinant protein is pivotal in understanding immune responses to cancer, particularly in relation to KRAS mutations, which are prevalent in various malignancies such as pancreatic, colorectal, and lung cancers. KRAS G12D is a frequently occurring oncogenic mutation that not only drives tumorigenesis but also poses challenges for targeted therapies. The HLA-A*11:01 allele, a common variant in certain populations, presents peptides derived from mutated proteins to CD8+ T cells, thereby playing a crucial role in the adaptive immune response. By creating a tetramer that combines HLA-A*11:01 with β2-microglobulin (B2M) and the specific KRAS G12D peptide, researchers can effectively identify and characterize T cell populations that respond to this mutation. This approach aids in deciphering the immune landscape surrounding KRAS-driven tumors, enhancing our understanding of how the immune system interacts with cancer cells. Ultimately, the development of this tetramer may contribute to the advancement of immunotherapeutic strategies, including personalized cancer vaccines and adoptive T cell therapies, thus providing insights into more effective treatments for patients with KRAS-mutant cancers.
